NCT05506605

Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance

Open-label, Single-arm, Unicenter and Pilot Study of a Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Fundacion Clinic per a la Recerca Biomédica · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase IV, open-label, single arm, unicenter and pilot study on virologically suppressed HIV infected adults with ETR resistance, to assess the efficacy of a Switch strategy from Etravirine (ETR) to Doravirine (DOR).

Conditions

• HIV-1-infection

Interventions

Type	Name	Description
DRUG	Doravirine 100Mg Tab	Switch from Etravirine to Doravirine

Timeline

• Start date: 2022-12-12
• Primary completion: 2024-12-01
• Completion: 2024-12-01
• First posted: 2022-08-18
• Last updated: 2023-09-21

Locations

1 site across 1 country: Spain